Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-078573 in chronic primary insomnia: randomized double-blind placebo- and zolpidem-controlled PSG study
2007-005194-56Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of almorexant in primary insomnia (3 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Change in sleep-maintenance endpoints (objective) at treatment start and Day 16 and Change in subjective sleep-maintenance endpoints over 2 weeks. Started May 2008; status: completed.
02
Drugs
almorexant
03
Conditions
primary insomnia
Beyond the preview
Go deeper on 2007-005194-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005194-56.